#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=The World Health Organisation recommends exclusive breastfeeding for infants up to six months of age , based on the clear health benefits of breastfeeding on mother-infant dyad .
3-1	17-20	The	organization[3]	new[3]	_	_
3-2	21-26	World	organization[3]	new[3]	_	_
3-3	27-33	Health	organization[3]	new[3]	_	_
3-4	34-46	Organisation	organization[3]	new[3]	_	_
3-5	47-57	recommends	_	_	_	_
3-6	58-67	exclusive	_	_	_	_
3-7	68-81	breastfeeding	_	_	_	_
3-8	82-85	for	_	_	_	_
3-9	86-93	infants	person[4]	new[4]	coref	5-1[0_4]
3-10	94-96	up	person[4]	new[4]	_	_
3-11	97-99	to	_	_	_	_
3-12	100-103	six	time[5]	new[5]	coref	7-29[36_5]
3-13	104-110	months	time[5]	new[5]	_	_
3-14	111-113	of	time[5]	new[5]	_	_
3-15	114-117	age	time[5]|abstract	new[5]|new	_	_
3-16	118-119	,	_	_	_	_
3-17	120-125	based	_	_	_	_
3-18	126-128	on	_	_	_	_
3-19	129-132	the	abstract[8]	new[8]	coref	7-2[29_8]
3-20	133-138	clear	abstract[8]	new[8]	_	_
3-21	139-145	health	abstract|abstract[8]	new|new[8]	_	_
3-22	146-154	benefits	abstract[8]	new[8]	_	_
3-23	155-157	of	_	_	_	_
3-24	158-171	breastfeeding	_	_	_	_
3-25	172-174	on	_	_	_	_
3-26	175-188	mother-infant	abstract[9]	new[9]	coref	16-19[125_9]
3-27	189-193	dyad	abstract[9]	new[9]	_	_
3-28	194-195	.	_	_	_	_

#Text=Indeed , there is a consensus regarding the association of breastfeeding with a reduced risk of respiratory and gastro-intestinal infections during the first year of life .
4-1	196-202	Indeed	_	_	_	_
4-2	203-204	,	_	_	_	_
4-3	205-210	there	_	_	_	_
4-4	211-213	is	_	_	_	_
4-5	214-215	a	abstract[10]	new[10]	_	_
4-6	216-225	consensus	abstract[10]	new[10]	_	_
4-7	226-235	regarding	_	_	_	_
4-8	236-239	the	abstract[11]	new[11]	_	_
4-9	240-251	association	abstract[11]	new[11]	_	_
4-10	252-254	of	_	_	_	_
4-11	255-268	breastfeeding	_	_	_	_
4-12	269-273	with	_	_	_	_
4-13	274-275	a	abstract[12]	new[12]	coref	5-13[18_12]
4-14	276-283	reduced	abstract[12]	new[12]	_	_
4-15	284-288	risk	abstract[12]	new[12]	_	_
4-16	289-291	of	abstract[12]	new[12]	_	_
4-17	292-303	respiratory	abstract[12]|abstract[13]	new[12]|new[13]	_	_
4-18	304-307	and	abstract[12]|abstract[13]	new[12]|new[13]	_	_
4-19	308-325	gastro-intestinal	abstract[12]|abstract[13]	new[12]|new[13]	_	_
4-20	326-336	infections	abstract[12]|abstract[13]	new[12]|new[13]	_	_
4-21	337-343	during	abstract[12]|abstract[13]	new[12]|new[13]	_	_
4-22	344-347	the	abstract[12]|abstract[13]|time[14]	new[12]|new[13]|new[14]	_	_
4-23	348-353	first	abstract[12]|abstract[13]|time[14]	new[12]|new[13]|new[14]	_	_
4-24	354-358	year	abstract[12]|abstract[13]|time[14]	new[12]|new[13]|new[14]	_	_
4-25	359-361	of	abstract[12]|abstract[13]|time[14]	new[12]|new[13]|new[14]	_	_
4-26	362-366	life	abstract[12]|abstract[13]|time[14]|abstract	new[12]|new[13]|new[14]|new	_	_
4-27	367-368	.	_	_	_	_

#Text=Infants , who were breastfed for longer periods , may also have a lower risk of developing obesity and type II diabetes at adulthood .
5-1	369-376	Infants	person	giv	_	_
5-2	377-378	,	_	_	_	_
5-3	379-382	who	_	_	_	_
5-4	383-387	were	_	_	_	_
5-5	388-397	breastfed	_	_	_	_
5-6	398-401	for	_	_	_	_
5-7	402-408	longer	time[17]	new[17]	_	_
5-8	409-416	periods	time[17]	new[17]	_	_
5-9	417-418	,	_	_	_	_
5-10	419-422	may	_	_	_	_
5-11	423-427	also	_	_	_	_
5-12	428-432	have	_	_	_	_
5-13	433-434	a	abstract[18]	giv[18]	coref	6-7[24_18]
5-14	435-440	lower	abstract[18]	giv[18]	_	_
5-15	441-445	risk	abstract[18]	giv[18]	_	_
5-16	446-448	of	_	_	_	_
5-17	449-459	developing	_	_	_	_
5-18	460-467	obesity	abstract	new	_	_
5-19	468-471	and	_	_	_	_
5-20	472-476	type	object	new	coref	6-14
5-21	477-479	II	abstract[21]	new[21]	coref	6-15[28_21]
5-22	480-488	diabetes	abstract[21]	new[21]	_	_
5-23	489-491	at	abstract[21]	new[21]	_	_
5-24	492-501	adulthood	abstract[21]|abstract	new[21]|new	_	_
5-25	502-503	.	_	_	_	_

#Text=For mothers , breastfeeding could limit the risk of developing ovarian cancer and type II diabetes .
6-1	504-507	For	_	_	_	_
6-2	508-515	mothers	person	new	coref	7-27
6-3	516-517	,	_	_	_	_
6-4	518-531	breastfeeding	_	_	_	_
6-5	532-537	could	_	_	_	_
6-6	538-543	limit	_	_	_	_
6-7	544-547	the	abstract[24]	giv[24]	_	_
6-8	548-552	risk	abstract[24]	giv[24]	_	_
6-9	553-555	of	_	_	_	_
6-10	556-566	developing	_	_	_	_
6-11	567-574	ovarian	person|abstract[26]	new|new[26]	_	_
6-12	575-581	cancer	abstract[26]	new[26]	_	_
6-13	582-585	and	_	_	_	_
6-14	586-590	type	object	giv	_	_
6-15	591-593	II	abstract[28]	giv[28]	coref	20-15[146_28]
6-16	594-602	diabetes	abstract[28]	giv[28]	_	_
6-17	603-604	.	_	_	_	_

#Text=Despite these benefits , breastfeeding prevalence remains relatively low , particularly in several high-income countries in North America and Europe , where only 40 % of mothers breastfeed six months after delivery .
7-1	605-612	Despite	_	_	_	_
7-2	613-618	these	abstract[29]	giv[29]	_	_
7-3	619-627	benefits	abstract[29]	giv[29]	_	_
7-4	628-629	,	_	_	_	_
7-5	630-643	breastfeeding	abstract[30]	new[30]	_	_
7-6	644-654	prevalence	abstract[30]	new[30]	_	_
7-7	655-662	remains	_	_	_	_
7-8	663-673	relatively	_	_	_	_
7-9	674-677	low	_	_	_	_
7-10	678-679	,	_	_	_	_
7-11	680-692	particularly	place[31]	new[31]	coref	8-12[42_31]
7-12	693-695	in	place[31]	new[31]	_	_
7-13	696-703	several	place[31]	new[31]	_	_
7-14	704-715	high-income	place[31]	new[31]	_	_
7-15	716-725	countries	place[31]	new[31]	_	_
7-16	726-728	in	place[31]	new[31]	_	_
7-17	729-734	North	place[31]|place[32]	new[31]|new[32]	_	_
7-18	735-742	America	place[31]|place[32]	new[31]|new[32]	_	_
7-19	743-746	and	place[31]	new[31]	_	_
7-20	747-753	Europe	place[31]|place	new[31]|new	_	_
7-21	754-755	,	_	_	_	_
7-22	756-761	where	_	_	_	_
7-23	762-766	only	quantity[34]	new[34]	_	_
7-24	767-769	40	quantity[34]	new[34]	_	_
7-25	770-771	%	quantity[34]	new[34]	_	_
7-26	772-774	of	quantity[34]	new[34]	_	_
7-27	775-782	mothers	quantity[34]|person	new[34]|giv	coref	14-17[105_0]
7-28	783-793	breastfeed	_	_	_	_
7-29	794-797	six	time[36]	giv[36]	_	_
7-30	798-804	months	time[36]	giv[36]	_	_
7-31	805-810	after	_	_	_	_
7-32	811-819	delivery	event	new	_	_
7-33	820-821	.	_	_	_	_

#Text=Exclusive breastfeeding rate is about 60 % at four months in Scandinavian countries , 35 % in the Netherlands , 16 % in the UK , and 10 % in France .
8-1	822-831	Exclusive	quantity[39]	new[39]	coref	8-5[40_39]
8-2	832-845	breastfeeding	abstract|quantity[39]	new|new[39]	_	_
8-3	846-850	rate	quantity[39]	new[39]	_	_
8-4	851-853	is	_	_	_	_
8-5	854-859	about	quantity[40]	giv[40]	_	_
8-6	860-862	60	quantity[40]	giv[40]	_	_
8-7	863-864	%	quantity[40]	giv[40]	_	_
8-8	865-867	at	quantity[40]	giv[40]	_	_
8-9	868-872	four	quantity[40]|time[41]	giv[40]|new[41]	_	_
8-10	873-879	months	quantity[40]|time[41]	giv[40]|new[41]	_	_
8-11	880-882	in	quantity[40]|time[41]	giv[40]|new[41]	_	_
8-12	883-895	Scandinavian	quantity[40]|time[41]|place[42]	giv[40]|new[41]|giv[42]	coref	20-7[143_42]
8-13	896-905	countries	quantity[40]|time[41]|place[42]	giv[40]|new[41]|giv[42]	_	_
8-14	906-907	,	quantity[40]	giv[40]	_	_
8-15	908-910	35	quantity[40]|quantity[43]	giv[40]|new[43]	coref	10-31[61_43]
8-16	911-912	%	quantity[40]|quantity[43]	giv[40]|new[43]	_	_
8-17	913-915	in	quantity[40]|quantity[43]	giv[40]|new[43]	_	_
8-18	916-919	the	quantity[40]|quantity[43]|place[44]	giv[40]|new[43]|new[44]	_	_
8-19	920-931	Netherlands	quantity[40]|quantity[43]|place[44]	giv[40]|new[43]|new[44]	_	_
8-20	932-933	,	quantity[40]	giv[40]	_	_
8-21	934-936	16	quantity[40]|quantity[45]	giv[40]|new[45]	_	_
8-22	937-938	%	quantity[40]|quantity[45]	giv[40]|new[45]	_	_
8-23	939-941	in	quantity[40]|quantity[45]	giv[40]|new[45]	_	_
8-24	942-945	the	quantity[40]|quantity[45]|place[46]	giv[40]|new[45]|new[46]	_	_
8-25	946-948	UK	quantity[40]|quantity[45]|place[46]	giv[40]|new[45]|new[46]	_	_
8-26	949-950	,	quantity[40]	giv[40]	_	_
8-27	951-954	and	quantity[40]	giv[40]	_	_
8-28	955-957	10	quantity[40]|quantity[47]	giv[40]|new[47]	_	_
8-29	958-959	%	quantity[40]|quantity[47]	giv[40]|new[47]	_	_
8-30	960-962	in	quantity[40]|quantity[47]	giv[40]|new[47]	_	_
8-31	963-969	France	quantity[40]|quantity[47]|place	giv[40]|new[47]|new	_	_
8-32	970-971	.	_	_	_	_

#Text=Early cessation of breastfeeding clearly is multifactorial .
9-1	972-977	Early	event[49]	new[49]	coref	10-26[60_49]
9-2	978-987	cessation	event[49]	new[49]	_	_
9-3	988-990	of	event[49]	new[49]	_	_
9-4	991-1004	breastfeeding	event[49]|person	new[49]|new	_	_
9-5	1005-1012	clearly	_	_	_	_
9-6	1013-1015	is	_	_	_	_
9-7	1016-1030	multifactorial	_	_	_	_
9-8	1031-1032	.	_	_	_	_

#Text=One of the main factors is the maternal perception of insufficient milk secretion to quell infant ’s hunger or support infant growth and leads to early cessation of breastfeeding in 35 % of cases .
10-1	1033-1036	One	abstract[51]	new[51]	coref	10-7[53_51]
10-2	1037-1039	of	abstract[51]	new[51]	_	_
10-3	1040-1043	the	abstract[51]|abstract[52]	new[51]|new[52]	_	_
10-4	1044-1048	main	abstract[51]|abstract[52]	new[51]|new[52]	_	_
10-5	1049-1056	factors	abstract[51]|abstract[52]	new[51]|new[52]	_	_
10-6	1057-1059	is	_	_	_	_
10-7	1060-1063	the	abstract[53]	giv[53]	_	_
10-8	1064-1072	maternal	abstract[53]	giv[53]	_	_
10-9	1073-1083	perception	abstract[53]	giv[53]	_	_
10-10	1084-1086	of	abstract[53]	giv[53]	_	_
10-11	1087-1099	insufficient	abstract[53]|substance[55]	giv[53]|new[55]	coref	11-29[70_55]
10-12	1100-1104	milk	abstract[53]|substance|substance[55]	giv[53]|new|new[55]	coref	11-4
10-13	1105-1114	secretion	abstract[53]|substance[55]	giv[53]|new[55]	_	_
10-14	1115-1117	to	_	_	_	_
10-15	1118-1123	quell	_	_	_	_
10-16	1124-1130	infant	person[56]|event[57]	new[56]|new[57]	coref|ana|coref|ana	10-21[0_56]|11-24[0_57]|10-21[0_56]|11-24[0_57]
10-17	1131-1133	’s	person[56]|event[57]	new[56]|new[57]	_	_
10-18	1134-1140	hunger	event[57]	new[57]	_	_
10-19	1141-1143	or	_	_	_	_
10-20	1144-1151	support	abstract[59]	new[59]	_	_
10-21	1152-1158	infant	person|abstract[59]	giv|new[59]	coref	13-45[99_0]
10-22	1159-1165	growth	abstract[59]	new[59]	_	_
10-23	1166-1169	and	_	_	_	_
10-24	1170-1175	leads	_	_	_	_
10-25	1176-1178	to	_	_	_	_
10-26	1179-1184	early	event[60]	giv[60]	_	_
10-27	1185-1194	cessation	event[60]	giv[60]	_	_
10-28	1195-1197	of	event[60]	giv[60]	_	_
10-29	1198-1211	breastfeeding	event[60]	giv[60]	_	_
10-30	1212-1214	in	_	_	_	_
10-31	1215-1217	35	quantity[61]	giv[61]	_	_
10-32	1218-1219	%	quantity[61]	giv[61]	_	_
10-33	1220-1222	of	quantity[61]	giv[61]	_	_
10-34	1223-1228	cases	quantity[61]|abstract	giv[61]|new	_	_
10-35	1229-1230	.	_	_	_	_

#Text=Perception of insufficient milk production is a complex , multifactorial issue that can have biological , social , or psychological determinants , and it often remains unclear whether the low milk secretion is real or only perceived .
11-1	1231-1241	Perception	abstract[63]	new[63]	coref	11-7[66_63]
11-2	1242-1244	of	abstract[63]	new[63]	_	_
11-3	1245-1257	insufficient	abstract[63]|abstract[65]	new[63]|new[65]	coref	12-14[75_65]
11-4	1258-1262	milk	abstract[63]|substance|abstract[65]	new[63]|giv|new[65]	coref	11-31
11-5	1263-1273	production	abstract[63]|abstract[65]	new[63]|new[65]	_	_
11-6	1274-1276	is	_	_	_	_
11-7	1277-1278	a	abstract[66]	giv[66]	_	_
11-8	1279-1286	complex	abstract[66]	giv[66]	_	_
11-9	1287-1288	,	abstract[66]	giv[66]	_	_
11-10	1289-1303	multifactorial	abstract[66]	giv[66]	_	_
11-11	1304-1309	issue	abstract[66]	giv[66]	_	_
11-12	1310-1314	that	_	_	_	_
11-13	1315-1318	can	_	_	_	_
11-14	1319-1323	have	_	_	_	_
11-15	1324-1334	biological	abstract[67]	new[67]	_	_
11-16	1335-1336	,	abstract[67]	new[67]	_	_
11-17	1337-1343	social	abstract[67]	new[67]	_	_
11-18	1344-1345	,	abstract[67]	new[67]	_	_
11-19	1346-1348	or	abstract[67]	new[67]	_	_
11-20	1349-1362	psychological	abstract[67]	new[67]	_	_
11-21	1363-1375	determinants	abstract[67]	new[67]	_	_
11-22	1376-1377	,	_	_	_	_
11-23	1378-1381	and	_	_	_	_
11-24	1382-1384	it	event	giv	_	_
11-25	1385-1390	often	_	_	_	_
11-26	1391-1398	remains	_	_	_	_
11-27	1399-1406	unclear	_	_	_	_
11-28	1407-1414	whether	_	_	_	_
11-29	1415-1418	the	substance[70]	giv[70]	coref	13-1[83_70]
11-30	1419-1422	low	substance[70]	giv[70]	_	_
11-31	1423-1427	milk	substance|substance[70]	giv|giv[70]	coref	12-15
11-32	1428-1437	secretion	substance[70]	giv[70]	_	_
11-33	1438-1440	is	_	_	_	_
11-34	1441-1445	real	_	_	_	_
11-35	1446-1448	or	_	_	_	_
11-36	1449-1453	only	_	_	_	_
11-37	1454-1463	perceived	_	_	_	_
11-38	1464-1465	.	_	_	_	_

#Text=Indeed , as a result of the lack of an objective marker of insufficient milk production and the importance of maternal psychology in breastfeeding duration , perceived milk insufficiency is probably much more common than true insufficient production .
12-1	1466-1472	Indeed	_	_	_	_
12-2	1473-1474	,	_	_	_	_
12-3	1475-1477	as	_	_	_	_
12-4	1478-1479	a	_	_	_	_
12-5	1480-1486	result	_	_	_	_
12-6	1487-1489	of	_	_	_	_
12-7	1490-1493	the	abstract[71]	new[71]	_	_
12-8	1494-1498	lack	abstract[71]	new[71]	_	_
12-9	1499-1501	of	abstract[71]	new[71]	_	_
12-10	1502-1504	an	abstract[71]|abstract[73]	new[71]|new[73]	_	_
12-11	1505-1514	objective	abstract[71]|abstract|abstract[73]	new[71]|new|new[73]	coref	27-15[209_0]
12-12	1515-1521	marker	abstract[71]|abstract[73]	new[71]|new[73]	_	_
12-13	1522-1524	of	abstract[71]|abstract[73]	new[71]|new[73]	_	_
12-14	1525-1537	insufficient	abstract[71]|abstract[73]|abstract[75]	new[71]|new[73]|giv[75]	coref	12-36[81_75]
12-15	1538-1542	milk	abstract[71]|abstract[73]|substance|abstract[75]	new[71]|new[73]|giv|giv[75]	coref	12-28
12-16	1543-1553	production	abstract[71]|abstract[73]|abstract[75]	new[71]|new[73]|giv[75]	_	_
12-17	1554-1557	and	abstract[71]	new[71]	_	_
12-18	1558-1561	the	abstract[71]|abstract[76]	new[71]|new[76]	_	_
12-19	1562-1572	importance	abstract[71]|abstract[76]	new[71]|new[76]	_	_
12-20	1573-1575	of	abstract[71]|abstract[76]	new[71]|new[76]	_	_
12-21	1576-1584	maternal	abstract[71]|abstract[76]|abstract[77]	new[71]|new[76]|new[77]	_	_
12-22	1585-1595	psychology	abstract[71]|abstract[76]|abstract[77]	new[71]|new[76]|new[77]	_	_
12-23	1596-1598	in	_	_	_	_
12-24	1599-1612	breastfeeding	_	_	_	_
12-25	1613-1621	duration	time	new	_	_
12-26	1622-1623	,	_	_	_	_
12-27	1624-1633	perceived	_	_	_	_
12-28	1634-1638	milk	substance|abstract[80]	giv|new[80]	coref|coref	13-3|13-3
12-29	1639-1652	insufficiency	abstract[80]	new[80]	_	_
12-30	1653-1655	is	_	_	_	_
12-31	1656-1664	probably	_	_	_	_
12-32	1665-1669	much	_	_	_	_
12-33	1670-1674	more	_	_	_	_
12-34	1675-1681	common	_	_	_	_
12-35	1682-1686	than	_	_	_	_
12-36	1687-1691	true	abstract[81]	giv[81]	coref	14-2[102_81]
12-37	1692-1704	insufficient	abstract[81]	giv[81]	_	_
12-38	1705-1715	production	abstract[81]	giv[81]	_	_
12-39	1716-1717	.	_	_	_	_

#Text=True insufficient milk secretion can result from many causes , ranging from inability to lactate due to breast abnormalities or endocrine disorder ( 5 % of women ) to difficulties in breastfeeding management , maternal stress and anxiety , or early food diversification in the infant .
13-1	1718-1722	True	substance[83]	giv[83]	_	_
13-2	1723-1735	insufficient	substance[83]	giv[83]	_	_
13-3	1736-1740	milk	substance|substance[83]	giv|giv[83]	coref	14-3
13-4	1741-1750	secretion	substance[83]	giv[83]	_	_
13-5	1751-1754	can	_	_	_	_
13-6	1755-1761	result	_	_	_	_
13-7	1762-1766	from	_	_	_	_
13-8	1767-1771	many	abstract[84]	new[84]	_	_
13-9	1772-1778	causes	abstract[84]	new[84]	_	_
13-10	1779-1780	,	_	_	_	_
13-11	1781-1788	ranging	_	_	_	_
13-12	1789-1793	from	_	_	_	_
13-13	1794-1803	inability	abstract[85]	new[85]	_	_
13-14	1804-1806	to	abstract[85]	new[85]	_	_
13-15	1807-1814	lactate	abstract[85]|substance[86]	new[85]|new[86]	_	_
13-16	1815-1818	due	abstract[85]|substance[86]	new[85]|new[86]	_	_
13-17	1819-1821	to	_	_	_	_
13-18	1822-1828	breast	place|abstract[88]	new|new[88]	_	_
13-19	1829-1842	abnormalities	abstract[88]	new[88]	_	_
13-20	1843-1845	or	_	_	_	_
13-21	1846-1855	endocrine	abstract[89]	new[89]	_	_
13-22	1856-1864	disorder	abstract[89]	new[89]	_	_
13-23	1865-1866	(	_	_	_	_
13-24	1867-1868	5	quantity[90]	new[90]	coref	23-27[0_90]
13-25	1869-1870	%	quantity[90]	new[90]	_	_
13-26	1871-1873	of	quantity[90]	new[90]	_	_
13-27	1874-1879	women	quantity[90]|person	new[90]|new	_	_
13-28	1880-1881	)	_	_	_	_
13-29	1882-1884	to	_	_	_	_
13-30	1885-1897	difficulties	abstract	new	_	_
13-31	1898-1900	in	_	_	_	_
13-32	1901-1914	breastfeeding	_	_	_	_
13-33	1915-1925	management	person	new	_	_
13-34	1926-1927	,	_	_	_	_
13-35	1928-1936	maternal	abstract|abstract[95]	new|new[95]	coref|coref	14-2|14-2
13-36	1937-1943	stress	abstract[95]	new[95]	_	_
13-37	1944-1947	and	_	_	_	_
13-38	1948-1955	anxiety	abstract	new	_	_
13-39	1956-1957	,	_	_	_	_
13-40	1958-1960	or	_	_	_	_
13-41	1961-1966	early	abstract[98]	new[98]	_	_
13-42	1967-1971	food	substance|abstract[98]	new|new[98]	_	_
13-43	1972-1987	diversification	abstract[98]	new[98]	_	_
13-44	1988-1990	in	abstract[98]	new[98]	_	_
13-45	1991-1994	the	abstract[98]|person[99]	new[98]|giv[99]	_	_
13-46	1995-2001	infant	abstract[98]|person[99]	new[98]|giv[99]	_	_
13-47	2002-2003	.	_	_	_	_

#Text=Although maternal milk production can be often increased through psychological support or maternal breastfeeding education , many healthy mothers are eager to enhance their milk production through various nutritional supplements .
14-1	2004-2012	Although	_	_	_	_
14-2	2013-2021	maternal	abstract|abstract[102]	giv|giv[102]	coref|coref	14-24[108_102]|14-24[108_102]
14-3	2022-2026	milk	substance|abstract[102]	giv|giv[102]	coref	14-25
14-4	2027-2037	production	abstract[102]	giv[102]	_	_
14-5	2038-2041	can	_	_	_	_
14-6	2042-2044	be	_	_	_	_
14-7	2045-2050	often	_	_	_	_
14-8	2051-2060	increased	_	_	_	_
14-9	2061-2068	through	_	_	_	_
14-10	2069-2082	psychological	abstract[103]	new[103]	_	_
14-11	2083-2090	support	abstract[103]	new[103]	_	_
14-12	2091-2093	or	_	_	_	_
14-13	2094-2102	maternal	event[104]	new[104]	_	_
14-14	2103-2116	breastfeeding	event[104]	new[104]	_	_
14-15	2117-2126	education	event[104]	new[104]	_	_
14-16	2127-2128	,	_	_	_	_
14-17	2129-2133	many	person[105]	giv[105]	ana	14-24[0_105]
14-18	2134-2141	healthy	person[105]	giv[105]	_	_
14-19	2142-2149	mothers	person[105]	giv[105]	_	_
14-20	2150-2153	are	_	_	_	_
14-21	2154-2159	eager	_	_	_	_
14-22	2160-2162	to	_	_	_	_
14-23	2163-2170	enhance	_	_	_	_
14-24	2171-2176	their	person|abstract[108]	giv|giv[108]	coref|coref|coref|coref	22-8[163_108]|27-30|22-8[163_108]|27-30
14-25	2177-2181	milk	substance|abstract[108]	giv|giv[108]	coref	21-12
14-26	2182-2192	production	abstract[108]	giv[108]	_	_
14-27	2193-2200	through	_	_	_	_
14-28	2201-2208	various	substance[109]	new[109]	_	_
14-29	2209-2220	nutritional	substance[109]	new[109]	_	_
14-30	2221-2232	supplements	substance[109]	new[109]	_	_
14-31	2233-2234	.	_	_	_	_

#Text=Several drugs and herbal preparations have traditionally been prescribed as galactologues : i. e. , substances that promote initiation or increase of lactation .
15-1	2235-2242	Several	substance[110]	new[110]	coref	16-1[117_110]
15-2	2243-2248	drugs	substance[110]	new[110]	_	_
15-3	2249-2252	and	_	_	_	_
15-4	2253-2259	herbal	object|abstract[112]	new|new[112]	_	_
15-5	2260-2272	preparations	abstract[112]	new[112]	_	_
15-6	2273-2277	have	_	_	_	_
15-7	2278-2291	traditionally	_	_	_	_
15-8	2292-2296	been	_	_	_	_
15-9	2297-2307	prescribed	_	_	_	_
15-10	2308-2310	as	_	_	_	_
15-11	2311-2324	galactologues	_	_	_	_
15-12	2325-2326	:	_	_	_	_
15-13	2327-2329	i.	_	_	_	_
15-14	2330-2332	e.	_	_	_	_
15-15	2333-2334	,	_	_	_	_
15-16	2335-2345	substances	substance	new	_	_
15-17	2346-2350	that	_	_	_	_
15-18	2351-2358	promote	_	_	_	_
15-19	2359-2369	initiation	event	new	_	_
15-20	2370-2372	or	_	_	_	_
15-21	2373-2381	increase	abstract[115]	new[115]	ana	17-1[0_115]
15-22	2382-2384	of	abstract[115]	new[115]	_	_
15-23	2385-2394	lactation	abstract[115]|event	new[115]|new	coref	17-26
15-24	2395-2396	.	_	_	_	_

#Text=Drugs like domperidone® or metoclopramide® carry the risk of adverse side effects such as arrhythmia or hypothyroidism in mother-children dyad .
16-1	2397-2402	Drugs	substance[117]	giv[117]	_	_
16-2	2403-2407	like	substance[117]	giv[117]	_	_
16-3	2408-2420	domperidone®	substance[117]|substance	giv[117]|new	_	_
16-4	2421-2423	or	substance[117]	giv[117]	_	_
16-5	2424-2439	metoclopramide®	substance[117]|substance	giv[117]|new	_	_
16-6	2440-2445	carry	_	_	_	_
16-7	2446-2449	the	abstract[120]	new[120]	_	_
16-8	2450-2454	risk	abstract[120]	new[120]	_	_
16-9	2455-2457	of	abstract[120]	new[120]	_	_
16-10	2458-2465	adverse	abstract[120]|abstract[122]	new[120]|new[122]	coref	19-20[141_122]
16-11	2466-2470	side	abstract[120]|abstract|abstract[122]	new[120]|new|new[122]	_	_
16-12	2471-2478	effects	abstract[120]|abstract[122]	new[120]|new[122]	_	_
16-13	2479-2483	such	abstract[120]|abstract[122]	new[120]|new[122]	_	_
16-14	2484-2486	as	abstract[120]|abstract[122]	new[120]|new[122]	_	_
16-15	2487-2497	arrhythmia	abstract[120]|abstract[122]|abstract	new[120]|new[122]|new	_	_
16-16	2498-2500	or	abstract[120]|abstract[122]	new[120]|new[122]	_	_
16-17	2501-2515	hypothyroidism	abstract[120]|abstract[122]|abstract[124]	new[120]|new[122]|new[124]	_	_
16-18	2516-2518	in	abstract[120]|abstract[122]|abstract[124]	new[120]|new[122]|new[124]	_	_
16-19	2519-2534	mother-children	abstract[120]|abstract[122]|abstract[124]|abstract[125]	new[120]|new[122]|new[124]|giv[125]	coref	28-12[222_125]
16-20	2535-2539	dyad	abstract[120]|abstract[122]|abstract[124]|abstract[125]	new[120]|new[122]|new[124]|giv[125]	_	_
16-21	2540-2541	.	_	_	_	_

#Text=That is why herbal galactologues like fennel , anise , barley , milk thistle , or garlic are becoming more and more popular for increasing lactation .
17-1	2542-2546	That	abstract	giv	coref	23-25[182_0]
17-2	2547-2549	is	_	_	_	_
17-3	2550-2553	why	_	_	_	_
17-4	2554-2560	herbal	substance[127]	new[127]	_	_
17-5	2561-2574	galactologues	substance[127]	new[127]	_	_
17-6	2575-2579	like	substance[127]	new[127]	_	_
17-7	2580-2586	fennel	substance[127]|plant	new[127]|new	_	_
17-8	2587-2588	,	substance[127]	new[127]	_	_
17-9	2589-2594	anise	substance[127]|plant	new[127]|new	_	_
17-10	2595-2596	,	substance[127]	new[127]	_	_
17-11	2597-2603	barley	substance[127]|plant	new[127]|new	_	_
17-12	2604-2605	,	substance[127]	new[127]	_	_
17-13	2606-2610	milk	substance[127]|plant[131]	new[127]|new[131]	_	_
17-14	2611-2618	thistle	substance[127]|plant[131]	new[127]|new[131]	_	_
17-15	2619-2620	,	substance[127]	new[127]	_	_
17-16	2621-2623	or	substance[127]	new[127]	_	_
17-17	2624-2630	garlic	substance[127]|plant	new[127]|new	_	_
17-18	2631-2634	are	_	_	_	_
17-19	2635-2643	becoming	_	_	_	_
17-20	2644-2648	more	_	_	_	_
17-21	2649-2652	and	_	_	_	_
17-22	2653-2657	more	_	_	_	_
17-23	2658-2665	popular	_	_	_	_
17-24	2666-2669	for	_	_	_	_
17-25	2670-2680	increasing	_	_	_	_
17-26	2681-2690	lactation	event	giv	coref	27-25
17-27	2691-2692	.	_	_	_	_

#Text=Among these herbal compounds , fenugreek probably is the most widely consumed .
18-1	2693-2698	Among	_	_	_	_
18-2	2699-2704	these	substance[134]	new[134]	_	_
18-3	2705-2711	herbal	substance[134]	new[134]	_	_
18-4	2712-2721	compounds	substance[134]	new[134]	_	_
18-5	2722-2723	,	_	_	_	_
18-6	2724-2733	fenugreek	substance	new	coref	19-1
18-7	2734-2742	probably	_	_	_	_
18-8	2743-2745	is	_	_	_	_
18-9	2746-2749	the	_	_	_	_
18-10	2750-2754	most	_	_	_	_
18-11	2755-2761	widely	_	_	_	_
18-12	2762-2770	consumed	_	_	_	_
18-13	2771-2772	.	_	_	_	_

#Text=Fenugreek has been used since antiquity in traditional Persian , Chinese , and Egyptian medicine for its range of therapeutic effects .
19-1	2773-2782	Fenugreek	substance	giv	ana	20-1
19-2	2783-2786	has	_	_	_	_
19-3	2787-2791	been	_	_	_	_
19-4	2792-2796	used	_	_	_	_
19-5	2797-2802	since	_	_	_	_
19-6	2803-2812	antiquity	time[137]	new[137]	_	_
19-7	2813-2815	in	time[137]	new[137]	_	_
19-8	2816-2827	traditional	time[137]|abstract[138]	new[137]|new[138]	ana	19-17[0_138]
19-9	2828-2835	Persian	time[137]|abstract[138]	new[137]|new[138]	_	_
19-10	2836-2837	,	time[137]|abstract[138]	new[137]|new[138]	_	_
19-11	2838-2845	Chinese	time[137]|abstract[138]	new[137]|new[138]	_	_
19-12	2846-2847	,	time[137]|abstract[138]	new[137]|new[138]	_	_
19-13	2848-2851	and	time[137]|abstract[138]	new[137]|new[138]	_	_
19-14	2852-2860	Egyptian	time[137]|abstract[138]	new[137]|new[138]	_	_
19-15	2861-2869	medicine	time[137]|abstract[138]	new[137]|new[138]	_	_
19-16	2870-2873	for	_	_	_	_
19-17	2874-2877	its	abstract|abstract[140]	giv|new[140]	ana|ana	21-9[0_140]|21-9[0_140]
19-18	2878-2883	range	abstract[140]	new[140]	_	_
19-19	2884-2886	of	abstract[140]	new[140]	_	_
19-20	2887-2898	therapeutic	abstract[140]|abstract[141]	new[140]|giv[141]	coref	20-10[145_141]
19-21	2899-2906	effects	abstract[140]|abstract[141]	new[140]|giv[141]	_	_
19-22	2907-2908	.	_	_	_	_

#Text=It is now increasingly consumed in Western countries for its presumed protective effects against diabetes , atherosclerosis , inflammation , and hypertriglyceridemia , as well as its putative role as a galactologue due , in part , to trigonelline , one of its main active ingredients .
20-1	2909-2911	It	substance	giv	ana	20-10
20-2	2912-2914	is	_	_	_	_
20-3	2915-2918	now	_	_	_	_
20-4	2919-2931	increasingly	_	_	_	_
20-5	2932-2940	consumed	_	_	_	_
20-6	2941-2943	in	_	_	_	_
20-7	2944-2951	Western	place[143]	giv[143]	_	_
20-8	2952-2961	countries	place[143]	giv[143]	_	_
20-9	2962-2965	for	place[143]	giv[143]	_	_
20-10	2966-2969	its	place[143]|substance|abstract[145]	giv[143]|giv|giv[145]	ana|ana	20-27|20-27
20-11	2970-2978	presumed	place[143]|abstract[145]	giv[143]|giv[145]	_	_
20-12	2979-2989	protective	place[143]|abstract[145]	giv[143]|giv[145]	_	_
20-13	2990-2997	effects	place[143]|abstract[145]	giv[143]|giv[145]	_	_
20-14	2998-3005	against	place[143]|abstract[145]	giv[143]|giv[145]	_	_
20-15	3006-3014	diabetes	place[143]|abstract[145]|abstract[146]	giv[143]|giv[145]|giv[146]	_	_
20-16	3015-3016	,	place[143]|abstract[145]|abstract[146]	giv[143]|giv[145]|giv[146]	_	_
20-17	3017-3032	atherosclerosis	place[143]|abstract[145]|abstract[146]|abstract	giv[143]|giv[145]|giv[146]|new	_	_
20-18	3033-3034	,	place[143]|abstract[145]|abstract[146]	giv[143]|giv[145]|giv[146]	_	_
20-19	3035-3047	inflammation	place[143]|abstract[145]|abstract[146]|abstract	giv[143]|giv[145]|giv[146]|new	_	_
20-20	3048-3049	,	place[143]|abstract[145]|abstract[146]	giv[143]|giv[145]|giv[146]	_	_
20-21	3050-3053	and	place[143]|abstract[145]|abstract[146]	giv[143]|giv[145]|giv[146]	_	_
20-22	3054-3074	hypertriglyceridemia	place[143]|abstract[145]|abstract[146]|abstract	giv[143]|giv[145]|giv[146]|new	_	_
20-23	3075-3076	,	place[143]|abstract[145]|abstract[146]	giv[143]|giv[145]|giv[146]	_	_
20-24	3077-3079	as	place[143]|abstract[145]|abstract[146]	giv[143]|giv[145]|giv[146]	_	_
20-25	3080-3084	well	place[143]|abstract[145]|abstract[146]	giv[143]|giv[145]|giv[146]	_	_
20-26	3085-3087	as	place[143]|abstract[145]|abstract[146]	giv[143]|giv[145]|giv[146]	_	_
20-27	3088-3091	its	place[143]|abstract[145]|abstract[146]|substance|abstract[151]	giv[143]|giv[145]|giv[146]|giv|new[151]	ana|ana	20-43|20-43
20-28	3092-3100	putative	place[143]|abstract[145]|abstract[146]|abstract[151]	giv[143]|giv[145]|giv[146]|new[151]	_	_
20-29	3101-3105	role	place[143]|abstract[145]|abstract[146]|abstract[151]	giv[143]|giv[145]|giv[146]|new[151]	_	_
20-30	3106-3108	as	place[143]|abstract[145]|abstract[146]|abstract[151]	giv[143]|giv[145]|giv[146]|new[151]	_	_
20-31	3109-3110	a	place[143]|abstract[145]|abstract[146]|abstract[151]	giv[143]|giv[145]|giv[146]|new[151]	_	_
20-32	3111-3123	galactologue	place[143]|abstract[145]|abstract[146]|abstract[151]	giv[143]|giv[145]|giv[146]|new[151]	_	_
20-33	3124-3127	due	place[143]|abstract[145]|abstract[146]|abstract[151]	giv[143]|giv[145]|giv[146]|new[151]	_	_
20-34	3128-3129	,	place[143]|abstract[145]|abstract[146]|abstract[151]	giv[143]|giv[145]|giv[146]|new[151]	_	_
20-35	3130-3132	in	place[143]|abstract[145]|abstract[146]|abstract[151]	giv[143]|giv[145]|giv[146]|new[151]	_	_
20-36	3133-3137	part	place[143]|abstract[145]|abstract[146]|abstract[151]	giv[143]|giv[145]|giv[146]|new[151]	_	_
20-37	3138-3139	,	place[143]|abstract[145]|abstract[146]|abstract[151]	giv[143]|giv[145]|giv[146]|new[151]	_	_
20-38	3140-3142	to	place[143]|abstract[145]|abstract[146]|abstract[151]	giv[143]|giv[145]|giv[146]|new[151]	_	_
20-39	3143-3155	trigonelline	place[143]|abstract[145]|abstract[146]|abstract[151]	giv[143]|giv[145]|giv[146]|new[151]	_	_
20-40	3156-3157	,	place[143]|abstract[145]|abstract[146]|abstract[151]	giv[143]|giv[145]|giv[146]|new[151]	_	_
20-41	3158-3161	one	place[143]|abstract[145]|abstract[146]|abstract[151]|object[152]	giv[143]|giv[145]|giv[146]|new[151]|new[152]	_	_
20-42	3162-3164	of	place[143]|abstract[145]|abstract[146]|abstract[151]|object[152]	giv[143]|giv[145]|giv[146]|new[151]|new[152]	_	_
20-43	3165-3168	its	place[143]|abstract[145]|abstract[146]|abstract[151]|object[152]|substance|substance[154]	giv[143]|giv[145]|giv[146]|new[151]|new[152]|giv|new[154]	coref|coref	22-6[161_0]|22-6[161_0]
20-44	3169-3173	main	place[143]|abstract[145]|abstract[146]|abstract[151]|object[152]|substance[154]	giv[143]|giv[145]|giv[146]|new[151]|new[152]|new[154]	_	_
20-45	3174-3180	active	place[143]|abstract[145]|abstract[146]|abstract[151]|object[152]|substance[154]	giv[143]|giv[145]|giv[146]|new[151]|new[152]|new[154]	_	_
20-46	3181-3192	ingredients	place[143]|abstract[145]|abstract[146]|abstract[151]|object[152]|substance[154]	giv[143]|giv[145]|giv[146]|new[151]|new[152]|new[154]	_	_
20-47	3193-3194	.	_	_	_	_

#Text=There is , however , little evidence for its effectiveness on milk yield .
21-1	3195-3200	There	_	_	_	_
21-2	3201-3203	is	_	_	_	_
21-3	3204-3205	,	_	_	_	_
21-4	3206-3213	however	abstract[155]	new[155]	_	_
21-5	3214-3215	,	abstract[155]	new[155]	_	_
21-6	3216-3222	little	abstract[155]	new[155]	_	_
21-7	3223-3231	evidence	abstract[155]	new[155]	_	_
21-8	3232-3235	for	abstract[155]	new[155]	_	_
21-9	3236-3239	its	abstract[155]|abstract|abstract[157]	new[155]|giv|new[157]	coref|coref	27-6[205_157]|27-6[205_157]
21-10	3240-3253	effectiveness	abstract[155]|abstract[157]	new[155]|new[157]	_	_
21-11	3254-3256	on	abstract[155]|abstract[157]	new[155]|new[157]	_	_
21-12	3257-3261	milk	abstract[155]|abstract[157]|substance|abstract[159]	new[155]|new[157]|giv|new[159]	coref|coref	22-8|22-8
21-13	3262-3267	yield	abstract[155]|abstract[157]|abstract[159]	new[155]|new[157]|new[159]	_	_
21-14	3268-3269	.	_	_	_	_

#Text=Whereas a positive effect of fenugreek on milk production was observed in various mammals , such as rabbit , buffalo , goat , or ewe ; the wide range of doses tested ( from 180 mg .
22-1	3270-3277	Whereas	_	_	_	_
22-2	3278-3279	a	abstract[160]	new[160]	coref	23-16[178_160]
22-3	3280-3288	positive	abstract[160]	new[160]	_	_
22-4	3289-3295	effect	abstract[160]	new[160]	_	_
22-5	3296-3298	of	abstract[160]	new[160]	_	_
22-6	3299-3308	fenugreek	abstract[160]|substance[161]	new[160]|giv[161]	coref	23-46[0_161]
22-7	3309-3311	on	abstract[160]|substance[161]	new[160]|giv[161]	_	_
22-8	3312-3316	milk	abstract[160]|substance[161]|substance|abstract[163]	new[160]|giv[161]|giv|giv[163]	coref|coref|coref|coref	23-20|23-20[180_163]|23-20|23-20[180_163]
22-9	3317-3327	production	abstract[160]|substance[161]|abstract[163]	new[160]|giv[161]|giv[163]	_	_
22-10	3328-3331	was	_	_	_	_
22-11	3332-3340	observed	_	_	_	_
22-12	3341-3343	in	_	_	_	_
22-13	3344-3351	various	animal[164]	new[164]	_	_
22-14	3352-3359	mammals	animal[164]	new[164]	_	_
22-15	3360-3361	,	animal[164]	new[164]	_	_
22-16	3362-3366	such	animal[164]	new[164]	_	_
22-17	3367-3369	as	animal[164]	new[164]	_	_
22-18	3370-3376	rabbit	animal[164]|animal	new[164]|new	coref	25-20
22-19	3377-3378	,	animal[164]	new[164]	_	_
22-20	3379-3386	buffalo	animal[164]|animal	new[164]|new	_	_
22-21	3387-3388	,	animal[164]	new[164]	_	_
22-22	3389-3393	goat	animal[164]|animal	new[164]|new	_	_
22-23	3394-3395	,	animal[164]	new[164]	_	_
22-24	3396-3398	or	animal[164]	new[164]	_	_
22-25	3399-3402	ewe	animal[164]|animal	new[164]|new	_	_
22-26	3403-3404	;	animal[164]	new[164]	_	_
22-27	3405-3408	the	animal[164]|quantity[169]	new[164]|new[169]	_	_
22-28	3409-3413	wide	animal[164]|quantity[169]	new[164]|new[169]	_	_
22-29	3414-3419	range	animal[164]|quantity[169]	new[164]|new[169]	_	_
22-30	3420-3422	of	animal[164]|quantity[169]	new[164]|new[169]	_	_
22-31	3423-3428	doses	animal[164]|quantity[169]|quantity	new[164]|new[169]|new	_	_
22-32	3429-3435	tested	_	_	_	_
22-33	3436-3437	(	_	_	_	_
22-34	3438-3442	from	_	_	_	_
22-35	3443-3446	180	quantity[171]	new[171]	_	_
22-36	3447-3449	mg	quantity[171]	new[171]	_	_
22-37	3450-3451	.	_	_	_	_

#Text=kg-1 . d-1 to 2.1 g. kg-1 . d-1 ) led to large discrepancies in the reported effect on milk production ( ranging from a 10 % increase to a 110 % increase ) , which makes it difficult to determine the effective dose of fenugreek .
23-1	3452-3456	kg-1	substance	new	coref	23-5[175_0]
23-2	3457-3458	.	_	_	_	_
23-3	3459-3462	d-1	quantity[173]	new[173]	appos	23-9[0_173]
23-4	3463-3465	to	quantity[173]	new[173]	_	_
23-5	3466-3469	2.1	quantity[173]|substance[175]	new[173]|giv[175]	_	_
23-6	3470-3472	g.	quantity[173]|quantity|substance[175]	new[173]|new|giv[175]	_	_
23-7	3473-3477	kg-1	quantity[173]|substance[175]	new[173]|giv[175]	_	_
23-8	3478-3479	.	_	_	_	_
23-9	3480-3483	d-1	quantity	giv	ana	23-38
23-10	3484-3485	)	_	_	_	_
23-11	3486-3489	led	_	_	_	_
23-12	3490-3492	to	_	_	_	_
23-13	3493-3498	large	abstract[177]	new[177]	_	_
23-14	3499-3512	discrepancies	abstract[177]	new[177]	_	_
23-15	3513-3515	in	abstract[177]	new[177]	_	_
23-16	3516-3519	the	abstract[177]|abstract[178]	new[177]|giv[178]	coref	24-8[188_178]
23-17	3520-3528	reported	abstract[177]|abstract[178]	new[177]|giv[178]	_	_
23-18	3529-3535	effect	abstract[177]|abstract[178]	new[177]|giv[178]	_	_
23-19	3536-3538	on	abstract[177]|abstract[178]	new[177]|giv[178]	_	_
23-20	3539-3543	milk	abstract[177]|abstract[178]|substance|abstract[180]	new[177]|giv[178]|giv|giv[180]	coref|coref|coref|coref	25-5|25-5[193_180]|25-5|25-5[193_180]
23-21	3544-3554	production	abstract[177]|abstract[178]|abstract[180]	new[177]|giv[178]|giv[180]	_	_
23-22	3555-3556	(	_	_	_	_
23-23	3557-3564	ranging	_	_	_	_
23-24	3565-3569	from	_	_	_	_
23-25	3570-3571	a	abstract[182]	giv[182]	_	_
23-26	3572-3574	10	abstract[182]	giv[182]	_	_
23-27	3575-3576	%	quantity|abstract[182]	giv|giv[182]	coref	23-32
23-28	3577-3585	increase	abstract[182]	giv[182]	_	_
23-29	3586-3588	to	abstract[182]	giv[182]	_	_
23-30	3589-3590	a	abstract[182]	giv[182]	_	_
23-31	3591-3594	110	abstract[182]	giv[182]	_	_
23-32	3595-3596	%	abstract[182]|quantity	giv[182]|giv	_	_
23-33	3597-3605	increase	abstract[182]	giv[182]	_	_
23-34	3606-3607	)	_	_	_	_
23-35	3608-3609	,	_	_	_	_
23-36	3610-3615	which	_	_	_	_
23-37	3616-3621	makes	_	_	_	_
23-38	3622-3624	it	quantity	giv	_	_
23-39	3625-3634	difficult	_	_	_	_
23-40	3635-3637	to	_	_	_	_
23-41	3638-3647	determine	_	_	_	_
23-42	3648-3651	the	quantity[185]	new[185]	_	_
23-43	3652-3661	effective	quantity[185]	new[185]	_	_
23-44	3662-3666	dose	quantity[185]	new[185]	_	_
23-45	3667-3669	of	quantity[185]	new[185]	_	_
23-46	3670-3679	fenugreek	quantity[185]|substance	new[185]|giv	coref	27-9
23-47	3680-3681	.	_	_	_	_

#Text=Moreover , other studies failed to demonstrate an effect in rabbits and goats .
24-1	3682-3690	Moreover	_	_	_	_
24-2	3691-3692	,	_	_	_	_
24-3	3693-3698	other	abstract[187]	new[187]	coref	25-2[191_187]
24-4	3699-3706	studies	abstract[187]	new[187]	_	_
24-5	3707-3713	failed	_	_	_	_
24-6	3714-3716	to	_	_	_	_
24-7	3717-3728	demonstrate	_	_	_	_
24-8	3729-3731	an	abstract[188]	giv[188]	_	_
24-9	3732-3738	effect	abstract[188]	giv[188]	_	_
24-10	3739-3741	in	abstract[188]	giv[188]	_	_
24-11	3742-3749	rabbits	abstract[188]|animal	giv[188]|new	_	_
24-12	3750-3753	and	abstract[188]	giv[188]	_	_
24-13	3754-3759	goats	abstract[188]|animal	giv[188]|new	_	_
24-14	3760-3761	.	_	_	_	_

#Text=In these studies , milk production was measured either by the weight – suckle – weight method ( in rabbit ) , or by milking ( in larger animals ) .
25-1	3762-3764	In	_	_	_	_
25-2	3765-3770	these	abstract[191]	giv[191]	coref	27-3[204_191]
25-3	3771-3778	studies	abstract[191]	giv[191]	_	_
25-4	3779-3780	,	_	_	_	_
25-5	3781-3785	milk	substance|abstract[193]	giv|giv[193]	coref|coref|coref|coref	26-11|26-11[201_193]|26-11|26-11[201_193]
25-6	3786-3796	production	abstract[193]	giv[193]	_	_
25-7	3797-3800	was	_	_	_	_
25-8	3801-3809	measured	_	_	_	_
25-9	3810-3816	either	place[194]	new[194]	coref	25-16[0_194]
25-10	3817-3819	by	place[194]	new[194]	_	_
25-11	3820-3823	the	place[194]	new[194]	_	_
25-12	3824-3830	weight	place[194]	new[194]	_	_
25-13	3831-3832	–	_	_	_	_
25-14	3833-3839	suckle	_	_	_	_
25-15	3840-3841	–	_	_	_	_
25-16	3842-3848	weight	place|abstract[196]	giv|new[196]	_	_
25-17	3849-3855	method	abstract[196]	new[196]	_	_
25-18	3856-3857	(	abstract[196]	new[196]	_	_
25-19	3858-3860	in	abstract[196]	new[196]	_	_
25-20	3861-3867	rabbit	abstract[196]|animal	new[196]|giv	_	_
25-21	3868-3869	)	abstract[196]	new[196]	_	_
25-22	3870-3871	,	_	_	_	_
25-23	3872-3874	or	_	_	_	_
25-24	3875-3877	by	_	_	_	_
25-25	3878-3885	milking	_	_	_	_
25-26	3886-3887	(	_	_	_	_
25-27	3888-3890	in	_	_	_	_
25-28	3891-3897	larger	animal[198]	new[198]	_	_
25-29	3898-3905	animals	animal[198]	new[198]	_	_
25-30	3906-3907	)	_	_	_	_
25-31	3908-3909	.	_	_	_	_

#Text=The latter methods do not , however , directly assess milk production in response to physiological suckling by the pups .
26-1	3910-3913	The	abstract[199]	new[199]	_	_
26-2	3914-3920	latter	abstract[199]	new[199]	_	_
26-3	3921-3928	methods	abstract[199]	new[199]	_	_
26-4	3929-3931	do	_	_	_	_
26-5	3932-3935	not	_	_	_	_
26-6	3936-3937	,	_	_	_	_
26-7	3938-3945	however	_	_	_	_
26-8	3946-3947	,	_	_	_	_
26-9	3948-3956	directly	_	_	_	_
26-10	3957-3963	assess	_	_	_	_
26-11	3964-3968	milk	substance|abstract[201]	giv|giv[201]	coref|coref|coref|coref	27-12|27-12[208_201]|27-12|27-12[208_201]
26-12	3969-3979	production	abstract[201]	giv[201]	_	_
26-13	3980-3982	in	_	_	_	_
26-14	3983-3991	response	abstract[202]	new[202]	_	_
26-15	3992-3994	to	abstract[202]	new[202]	_	_
26-16	3995-4008	physiological	abstract[202]	new[202]	_	_
26-17	4009-4017	suckling	abstract[202]	new[202]	_	_
26-18	4018-4020	by	_	_	_	_
26-19	4021-4024	the	animal[203]	new[203]	_	_
26-20	4025-4029	pups	animal[203]	new[203]	_	_
26-21	4030-4031	.	_	_	_	_

#Text=Moreover , these studies evaluated the effectiveness of fenugreek to increase milk production with the aim of productivity , under otherwise optimal conditions of lactation , as opposed to mothers challenged by their perception of insufficient milk production .
27-1	4032-4040	Moreover	_	_	_	_
27-2	4041-4042	,	_	_	_	_
27-3	4043-4048	these	abstract[204]	giv[204]	coref	28-5[219_204]
27-4	4049-4056	studies	abstract[204]	giv[204]	_	_
27-5	4057-4066	evaluated	_	_	_	_
27-6	4067-4070	the	abstract[205]	giv[205]	_	_
27-7	4071-4084	effectiveness	abstract[205]	giv[205]	_	_
27-8	4085-4087	of	abstract[205]	giv[205]	_	_
27-9	4088-4097	fenugreek	abstract[205]|substance	giv[205]|giv	coref	28-15
27-10	4098-4100	to	abstract[205]	giv[205]	_	_
27-11	4101-4109	increase	abstract[205]	giv[205]	_	_
27-12	4110-4114	milk	abstract[205]|substance|abstract[208]	giv[205]|giv|giv[208]	coref|coref|coref|coref	27-37|27-36[217_208]|27-37|27-36[217_208]
27-13	4115-4125	production	abstract[205]|abstract[208]	giv[205]|giv[208]	_	_
27-14	4126-4130	with	abstract[205]|abstract[208]	giv[205]|giv[208]	_	_
27-15	4131-4134	the	abstract[205]|abstract[208]|abstract[209]	giv[205]|giv[208]|giv[209]	_	_
27-16	4135-4138	aim	abstract[205]|abstract[208]|abstract[209]	giv[205]|giv[208]|giv[209]	_	_
27-17	4139-4141	of	abstract[205]|abstract[208]|abstract[209]	giv[205]|giv[208]|giv[209]	_	_
27-18	4142-4154	productivity	abstract[205]|abstract[208]|abstract[209]|abstract	giv[205]|giv[208]|giv[209]|new	_	_
27-19	4155-4156	,	abstract[205]	giv[205]	_	_
27-20	4157-4162	under	abstract[205]	giv[205]	_	_
27-21	4163-4172	otherwise	abstract[205]|abstract[211]	giv[205]|new[211]	_	_
27-22	4173-4180	optimal	abstract[205]|abstract[211]	giv[205]|new[211]	_	_
27-23	4181-4191	conditions	abstract[205]|abstract[211]	giv[205]|new[211]	_	_
27-24	4192-4194	of	abstract[205]|abstract[211]	giv[205]|new[211]	_	_
27-25	4195-4204	lactation	abstract[205]|abstract[211]|event	giv[205]|new[211]|giv	_	_
27-26	4205-4206	,	_	_	_	_
27-27	4207-4209	as	_	_	_	_
27-28	4210-4217	opposed	_	_	_	_
27-29	4218-4220	to	_	_	_	_
27-30	4221-4228	mothers	person	giv	ana	27-33
27-31	4229-4239	challenged	_	_	_	_
27-32	4240-4242	by	_	_	_	_
27-33	4243-4248	their	person|abstract[215]	giv|new[215]	_	_
27-34	4249-4259	perception	abstract[215]	new[215]	_	_
27-35	4260-4262	of	abstract[215]	new[215]	_	_
27-36	4263-4275	insufficient	abstract[215]|abstract[217]	new[215]|giv[217]	coref	29-9[228_217]
27-37	4276-4280	milk	abstract[215]|substance|abstract[217]	new[215]|giv|giv[217]	coref	29-9
27-38	4281-4291	production	abstract[215]|abstract[217]	new[215]|giv[217]	_	_
27-39	4292-4293	.	_	_	_	_

#Text=Finally , none of these studies evaluated the metabolic status of mother-infant dyad following fenugreek supplementation .
28-1	4294-4301	Finally	_	_	_	_
28-2	4302-4303	,	_	_	_	_
28-3	4304-4308	none	abstract[218]	new[218]	_	_
28-4	4309-4311	of	abstract[218]	new[218]	_	_
28-5	4312-4317	these	abstract[218]|abstract[219]	new[218]|giv[219]	_	_
28-6	4318-4325	studies	abstract[218]|abstract[219]	new[218]|giv[219]	_	_
28-7	4326-4335	evaluated	_	_	_	_
28-8	4336-4339	the	abstract[221]	new[221]	_	_
28-9	4340-4349	metabolic	person|abstract[221]	new|new[221]	_	_
28-10	4350-4356	status	abstract[221]	new[221]	_	_
28-11	4357-4359	of	abstract[221]	new[221]	_	_
28-12	4360-4373	mother-infant	abstract[221]|abstract[222]	new[221]|giv[222]	_	_
28-13	4374-4378	dyad	abstract[221]|abstract[222]	new[221]|giv[222]	_	_
28-14	4379-4388	following	_	_	_	_
28-15	4389-4398	fenugreek	substance|substance[224]	giv|new[224]	coref|coref	29-7[226_0]|29-7[226_0]
28-16	4399-4414	supplementation	substance[224]	new[224]	_	_
28-17	4415-4416	.	_	_	_	_

#Text=Thus , the true efficacy of fenugreek on milk production in an animal model submitted to a breastfeeding challenge remains to be ascertained .
29-1	4417-4421	Thus	_	_	_	_
29-2	4422-4423	,	_	_	_	_
29-3	4424-4427	the	abstract[225]	new[225]	_	_
29-4	4428-4432	true	abstract[225]	new[225]	_	_
29-5	4433-4441	efficacy	abstract[225]	new[225]	_	_
29-6	4442-4444	of	abstract[225]	new[225]	_	_
29-7	4445-4454	fenugreek	abstract[225]|substance[226]	new[225]|giv[226]	_	_
29-8	4455-4457	on	abstract[225]|substance[226]	new[225]|giv[226]	_	_
29-9	4458-4462	milk	abstract[225]|substance[226]|substance|abstract[228]	new[225]|giv[226]|giv|giv[228]	_	_
29-10	4463-4473	production	abstract[225]|substance[226]|abstract[228]	new[225]|giv[226]|giv[228]	_	_
29-11	4474-4476	in	abstract[225]	new[225]	_	_
29-12	4477-4479	an	abstract[225]|abstract[230]	new[225]|new[230]	_	_
29-13	4480-4486	animal	abstract[225]|person|abstract[230]	new[225]|new|new[230]	_	_
29-14	4487-4492	model	abstract[225]|abstract[230]	new[225]|new[230]	_	_
29-15	4493-4502	submitted	_	_	_	_
29-16	4503-4505	to	_	_	_	_
29-17	4506-4507	a	event[231]	new[231]	_	_
29-18	4508-4521	breastfeeding	event[231]	new[231]	_	_
29-19	4522-4531	challenge	event[231]	new[231]	_	_
29-20	4532-4539	remains	_	_	_	_
29-21	4540-4542	to	_	_	_	_
29-22	4543-4545	be	_	_	_	_
29-23	4546-4557	ascertained	_	_	_	_
29-24	4558-4559	.	_	_	_	_
